Evidence map›Paper›PMID 39388263›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant.

Patrick J Carmody, Francis J Roushar, Austin Tedman, Wei Wang, Madeline Herwig, Minsoo Kim, Eli F McDonald, Karen Noguera, Jennifer Wong-Roushar, Jon-Luc Poirier and 8 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Patrick J Carmody *Department of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Francis J Roushar *Department of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Austin TedmanThe James Tarpo Junior and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907.
Wei WangDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233.
Madeline HerwigDepartment of Chemistry, Vanderbilt University, Nashville, TN 37240.
Minsoo KimDepartment of Chemistry, Vanderbilt University, Nashville, TN 37240.
Eli F McDonaldDepartment of Chemistry, Vanderbilt University, Nashville, TN 37240.
Karen NogueraDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Jennifer Wong-RousharDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.ORCID 0000-0002-3278-3711
Jon-Luc PoirierDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Nathan B ZeltDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Ben T PockrassDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Andrew G McKeeDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Charles P KuntzThe James Tarpo Junior and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907.
S Vamsee RajuDepartment of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233.
Lars PlateDepartment of Chemistry, Vanderbilt University, Nashville, TN 37240.ORCID 0000-0003-4363-6116
Wesley D PennDepartment of Chemistry, Indiana University Bloomington, Bloomington, IN 47401.
Jonathan P SchlebachThe James Tarpo Junior and Margaret Tarpo Department of Chemistry, Purdue University, West Lafayette, IN 47907.ORCID 0000-0003-0955-7633

Funding

UAB CF Research and Translation Core CenterP30DK072482 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AMIT GAGGAR · 2007 to 2026
$23.0M
Rational optimization of combinatorial therapies for the treatment of rare cystic fibrosis variantsR01HL167046 · NHLBI · PURDUE UNIVERSITY · PI Lars Plate, Jonathan Patrick Schlebach · 2023 to 2026
$2.7M
Graduate Training Program in Quantitative and Chemical Biology at Indiana University BloomingtonT32GM131994 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI JARED C LEWIS · 2019 to 2026
$2.4M
Molecular Mechanisms of Membrane Protein Misfolding and Quality Control in Cellular ProteostasisR35GM152086 · NIGMS · PURDUE UNIVERSITY · PI Jonathan Patrick Schlebach · 2024 to 2026
$1.5M
Stimulation of Ribosomal Frameshifting by Cotranslational Membrane Protein Folding and MisfoldingR01GM138845 · NIGMS · TRUSTEES OF INDIANA UNIVERSITY · PI SCHLEBACH, JONATHAN PATRICK · 2021 to 2024
$1.2M
HHS | NIH | National Institute of General Medical Sciences (NIGMS) R01GM138845HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM152086NHLBI NIH HHS R01 HL167046NIDDK NIH HHS P30 DK072482NIGMS NIH HHS R01 GM138845NIGMS NIH HHS R35 GM152086NIGMS NIH HHS T32 GM131994
6 · The paper itself

Abstract

The cotranslational misfolding of the cystic fibrosis transmembrane conductance regulator chloride channel (CFTR) plays a central role in the molecular basis of CF. The misfolding of the most common CF variant (ΔF508) remodels both the translational regulation and quality control of CFTR. Nevertheless, it is unclear how the misassembly of the nascent polypeptide may directly influence the activity of the translation machinery. In this work, we identify a structural motif within the CFTR transcript that stimulates efficient -1 ribosomal frameshifting and triggers the premature termination of translation. Though this motif does not appear to impact the interactome of wild-type CFTR, silent mutations that disrupt this RNA structure alter the association of nascent ΔF508 CFTR with numerous translation and quality control proteins. Moreover, disrupting this RNA structure enhances the functional gating of the ΔF508 CFTR channel at the plasma membrane and its pharmacological rescue by the CFTR modulators contained in the CF drug Trikafta. The effects of the RNA structure on ΔF508 CFTR appear to be attenuated in the absence of the ER membrane protein complex, which was previously found to modulate ribosome collisions during "preemptive quality control" of a misfolded CFTR homolog. Together, our results reveal that ribosomal frameshifting selectively modulates the assembly, function, and pharmacological rescue of a misfolded CFTR variant. These findings suggest that interactions between the nascent chain, quality control machinery, and ribosome may dynamically modulate ribosomal frameshifting in order to tune the processivity of translation in response to cotranslational misfolding.

Indexed as

Cystic Fibrosis Transmembrane Conductance RegulatorFrameshifting, RibosomalProtein FoldingCystic FibrosisHumansMutationNucleic Acid ConformationProtein BiosynthesisRibosomesCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorCFTRmembrane protein foldingprogrammed ribosomal frameshiftingproteostasisribosome

Identifiers

PMID39388263
PMCPMC11494300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.